EGFR and non-small cell lung carcinoma: The identification of activating EGFR mutations as actionable driver oncogenes revolutionized the management of advanced NSCLC, establishing a biomarker-driven treatment paradigm.41 Currently, third-generation EGFR-TKIs have become the standard of care for first-line treatment in patients with common EGFR mutations and second or above-line treatments to patients with acquired EGFR T790M mutation.42 Despite their marked efficacy, not all of them can benefit and resistance remains a critical fundamental challenge.